Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. [electronic resource]
Producer: 20190408Description: 953-964 p. digitalISSN:- 1474-5488
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Dexamethasone -- therapeutic use
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Infusions, Intravenous
- Lenalidomide -- therapeutic use
- Male
- Multiple Myeloma -- drug therapy
- Neoplasm Invasiveness -- pathology
- Neoplasm Staging
- Oligopeptides -- therapeutic use
- Prognosis
- Proteasome Inhibitors -- therapeutic use
- Recurrence
- Risk Assessment
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.